

MGC028
Nontargeting Control ADC
A375.S2 Cells
% Viability
(Alamar Blue)
100
75
50
25
0
0.01
1
100
10000
mAb [pM]

FIG. 1A



MGC028
Nontargeting Control ADC
Calu-3 Cells
% Viability
(Alamar Blue)
100
75
50
25
0
0.01
1
100
10000
mAb [pM]

FIG. 1B



HPAF-II
MGC028
Nontargeting Control ADC
% Viability
(Alamar Blue)
100
75
50
25
0
0.001
0.1
10
1000
100000
mAb [pM]

FIG. 1C



NCI-H1975 Cells
ADCC Assay (E:T = 30:1)
MGA027
MGC028
Nontargeting Control ADC
% of Cytotoxicity
20
15
10
5
0
-5
0
1
100
mAb [nM]

FIG. 2B



NCI-H1703 Cells
ADCC Assay (E:T = 30:1)
MGA027
MGC028
Nontargeting Control ADC
% of Cytotoxicity
30
20
10
0
-10
0
1
100
mAb [nM]

FIG. 2A



Hs746T Cells
ADCC Assay (E:T = 30:1)
MGA027
MGC028
Nontargeting Control ADC
% of Cytotoxicity
0
10
20
30
40
0
1
100
mAb [nM]

FIG. 2D



HPAF-II Cells
ADCC Assay (E:T = 30:1)
MGA027
MGC028
Nontargeting Control ADC
% of Cytotoxicity
0
5
10
15
0
1
100
mAb [nM]

FIG. 2C



hADAM9
cynoADAM9
MGA027
MGC028
RU
Time
s
70
50
30
10
-10
-50
0
50
100
200
300

FIG. 3A



CD16A 158V
CD16A 158F
MGA027
MGC028
K_D=1960nM
K_D=3600nM
1000nM
RU
Time
s

FIG. 3B



HPAF-II
Pancreatic Adenocarcinoma
Mean Tumor Volume (mm3)
2000
1500
1000
500
0
0 10 20 30 40 50 60 70 80 90 100
Day (post treatment)
Vehicle (FB)
MGC028 [10 mg/kg]
MGC028 [6 mg/kg]
MGC028 [3 mg/kg]
MGC028 [1 mg/kg]
Nontargeting Control ADC [10 mg/kg]
Nontargeting Control ADC [6 mg/kg]
Nontargeting Control ADC [3 mg/kg]
Nontargeting Control ADC [1 mg/kg]

FIG. 4



Capan-1
Pancreatic Adenocarcinoma
Mean Tumor Volume (mm³)
2500
2000
1500
1000
500
0
0 10 20 30 40 50 60 70 80 90 100
Day (post treatment)
Vehicle (FB)
MGC028 [10 mg/kg]
MGC028 [6 mg/kg]
MGC028 [3 mg/kg]
MGC028 [1 mg/kg]
Nontargeting Control ADC [10 mg/kg]
Nontargeting Control ADC [6 mg/kg]
Nontargeting Control ADC [3 mg/kg]
Nontargeting Control ADC [1 mg/kg]

FIG. 5



Hs746T
Gastric Carcinoma
Mean Tumor Volume (mm³)
3000
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
70
80
90
Day (post treatment)
Vehicle (FB)
MGC028 [10 mg/kg]
MGC028 [6 mg/kg]
MGC028 [3 mg/kg]
MGC028 [1 mg/kg]
Nontargeting Control ADC [10 mg/kg]
Nontargeting Control ADC [6 mg/kg]
Nontargeting Control ADC [3 mg/kg]
Nontargeting Control ADC [1 mg/kg]

FIG. 6



NCI-H1975
Lung Adenocarcinoma
Mean Tumor Volume (mm³)
3000
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
70
80
Day (post treatment)
Vehicle (FB)
MGC028 [10 mg/kg]
MGC028 [6 mg/kg]
MGC028 [3 mg/kg]
MGC028 [1 mg/kg]
Nontargeting Control ADC [10 mg/kg]
Nontargeting Control ADC [6 mg/kg]
Nontargeting Control ADC [3 mg/kg]
Nontargeting Control ADC [1 mg/kg]

FIG. 7



Calu-3
NSCLC Adenocarcinoma
Mean Tumor Volume (mm³)
2500
2000
1500
1000
500
0
0 10 20 30 40 50 60 70 80 90 100
Day (post treatment)
Vehicle (FB)
MGC028 [10 mg/kg]
MGC028 [6 mg/kg]
MGC028 [3 mg/kg]
MGC028 [1 mg/kg]
Nontargeting Control ADC [10mg/kg]
Nontargeting Control ADC [6 mg/kg]
Nontargeting Control ADC [3 mg/kg]
Nontargeting Control ADC [1 mg/kg]

FIG. 8



NCI-H1703
NSCLC Squamous
Mean Tumor Volume (mm³)
2500
2000
1500
1000
500
0
0 10 20 30 40 50 60 70 80 90 100 110
Day (post treatment)
Vehicle (FB)
MGC028 [10 mg/kg]
MGC028 [6 mg/kg]
MGC028 [3 mg/kg]
Nontargeting Control ADC [10 mg/kg]
Nontargeting Control ADC [6 mg/kg]
Nontargeting Control ADC [3 mg/kg]

FIG. 9



SW48
Colorectal Adenocarcinoma
Mean Tumor Volume (mm³)
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
70
80
90
Day (post treatment)
Vehicle (FB)
MGC028 [10 mg/kg]
MGC028 [6 mg/kg]
MGC028 [3 mg/kg]
MGC028 [1 mg/kg]
Nontargeting Control ADC [10 mg/kg]
Nontargeting Control ADC [6 mg/kg]
Nontargeting Control ADC [3 mg/kg]
Nontargeting Control ADC [1 mg/kg]

FIG. 10



Detroit 562
SCCHN
Mean Tumor Volume (mm3)
3000
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
70
Day (post treatment)
Vehicle (FB)
MGC028 [10 mg/kg]
MGC028 [6 mg/kg]
MGC028 [3 mg/kg]
MGC028 [1 mg/kg]
Nontargeting Control ADC [10 mg/kg]
Nontargeting Control ADC [6 mg/kg
Nontargeting Control ADC [3 mg/kg]
Nontargeting Control ADC [1 mg/kg]

FIG. 11



A
SW48
Colorectal Adenocarcinoma
Mean Tumor Volume (mm³)
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
Day (post treatment)
Vehicle (FB)
MGC028 [10 mg/kg]
MGA027 [10mg/kg]
Exatecan [0.142 mg/kg]
MGA027 [10 mg/kg] + Exatecan [0.142 mg/kg]

FIG. 12A



B
NCI-H1975
Lung Adenocarcinoma
Vehicle (FB)
MGC028 [10 mg/kg]
MGA027 [10 mg/kg]
Exatecan [0.142 mg/kg]
MGA027 [10 mg/kg] + Exatecan [0.142]
Mean Tumor Volume (mm3)
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
Day (post treatment)

FIG. 12B



Cholangiocarcinoma
Vehicle (FB)
MGC028 [10 mg/kg] Q2W x 2
Mean Tumor Volume (mm3)
3000
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
70
80
90
Day (post treatment)

FIG. 13



Pancreatic Adenocarcinoma
Vehicle (FB)
MGC028 [10 mg/kg] Q2W x 2
Mean Tumor Volume (mm³)
2000
1500
1000
500
0
0
10
20
30
40
50
60
Day (post treatment)

FIG. 14



Pancreatic Adenocarcinoma
Vehicle (FB)
MGC028 [10 mg/kg] Q2W x 2
Mean Tumor Volume (mm³)
3000
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
70
Day (post treatment)

FIG. 15



NSCLC Adenocarcinoma
Vehicle (FB)
MGC028 [10 mg/kg] Q2W x 2
Mean Tumor Volume (mm3)
3000
2500
2000
1500
1000
500
0
0
10
20
30
40
50
Day (post treatment)

FIG. 16



NSCLC Adenocarcinoma
Vehicle (FB)
MGC028 [10 mg/kg] Q2W x 2
Mean Tumor Volume (mm3)
2000
1500
1000
500
0
0
10
20
30
40
50
60
70
Days (post treatment)

FIG. 17



Colorectal Cancer
Vehicle (FB)
MGC028 [10 mg/kg Q2W x 2]
Mean Tumor Volume (mm³)
2000
1500
1000
500
0
0
10
20
30
40
50
Day (post treatment)

FIG. 18



SCCHN
Vehicle (FB)
MGC028 [10 mg/kg] Q2W x 2
Mean Tumor Volume (mm³)
1500
1000
500
0
0
10
20
30
40
50
60
70
80
Days (post treatment)

FIG. 19



Mouse Plasma
Human Plasma
Cyno Plasma
DAR
DAR by LC-MS
4.3
4.2
4.1
4.0
3.9
3.8
3.7
0
50
100
150
200
Time: Hours

FIG. 20




FIG. 21B




FIG. 21A




FIG. 21D




FIG. 21C




FIG. 21F




FIG. 21E